Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $2.3 million.

  • NovaBay Pharmaceuticals' Cash & Equivalents rose 19755.15% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 19755.15%. This contributed to the annual value of $430000.0 for FY2024, which is 8529.41% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Cash & Equivalents of $2.3 million as of Q3 2025, which was up 19755.15% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Cash & Equivalents ranged from a high of $10.5 million in Q1 2021 and a low of $430000.0 during Q4 2024
  • Its 5-year average for Cash & Equivalents is $4.8 million, with a median of $3.9 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8529.41% in 2024, then soared by 61158.46% in 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Cash & Equivalents (Quarter) stood at $7.5 million in 2021, then decreased by 28.54% to $5.4 million in 2022, then tumbled by 45.47% to $2.9 million in 2023, then plummeted by 85.29% to $430000.0 in 2024, then skyrocketed by 436.98% to $2.3 million in 2025.
  • Its Cash & Equivalents was $2.3 million in Q3 2025, compared to $5.3 million in Q2 2025 and $8.5 million in Q1 2025.